Latest Breaking News On - Helsinn investment fund - Page 1 : comparemela.com

OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)

/PRNewswire/ OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today.

United statesOrange county convention centerAl iskandariyahPrnewswire oncoresponseJulie rathbunBuchang pharmaHelsinn investment fundRedmile groupQatar investment authorityWilliam marsh rice universityMd anderson cancer centerAlexandria real estate equitiesAmerican association for cancer research annual meetingRathbun communicationsElite cancer respondersAmerican association

NeoPhore completes extension to Series B financing to further advance discovery pipeline

/PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B.

United kingdomEast lothianMatthew bakerRobert jamesHelsinn investment fundUniversity of turinElement capitalAstellas venture managementUniversity of londonAstellas pharma incB future health fundPhoremost ltdPioneer fundMemorial sloan kettering cancer centerNeophore limitedClaris ventures

NeoPhore completes extension to Series B financing to further advance discovery pipeline

NeoPhore completes extension to Series B financing to further advance discovery pipeline
prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomEast lothianMatthew bakerRobert jamesHelsinn investment fundUniversity of turinElement capitalAstellas venture managementUniversity of londonAstellas pharma incB future health fundPhoremost ltdPioneer fundMemorial sloan kettering cancer centerNeophore limitedClaris ventures

OncoResponse to Present at Upcoming Investor Conferences

/PRNewswire/ OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today.

Al iskandariyahPrnewswire oncoresponsePiper sandlerJulie rathbunHelsinn investment fundNews center events presentationsRedmile groupQatar investment authorityWilliam marsh rice universityMd anderson cancer centerCapital markets healthcare private company conferenceAlexandria real estate equitiesMagnetar groupOncoresponse incRathbun communicationsClifford stocks

GenEp, Inc : GenEp Raises $1 45 Million Seed Financing

Financing will support development of first-in-class CNS-selective sodium channel modulatorsCHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies

United statesCommonwealth of virginiaUniversity of virginiaManoj patelKostenloser wertpapierhandelAngelini pharmaGerry brunkMarianne bjordalAndrewj krouseAndrew krouseHelsinn investment fundSeed fundUniversity of virginia drJazz pharmaceuticalsLicensing ventures groupAngelini lumira biosciences fund